WALEZA 160 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

waleza 160 mg filmsko obložene tablete

alkaloid - int d.o.o. - valsartan - filmsko obložena tableta - valsartan 160 mg / 1 tableta - valsartan

WALEZA 40 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

waleza 40 mg filmsko obložene tablete

alkaloid - int d.o.o. - valsartan - filmsko obložena tableta - valsartan 40 mg / 1 tableta - valsartan

WALEZA 80 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

waleza 80 mg filmsko obložene tablete

alkaloid - int d.o.o. - valsartan - filmsko obložena tableta - valsartan 80 mg / 1 tableta - valsartan

Imbruvica Evropska unija - slovenščina - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Fampridine Accord Evropska unija - slovenščina - EMA (European Medicines Agency)

fampridine accord

accord healthcare s.l.u. - fampridine - multiple skleroza - druga zdravila na živčnem sistemu - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Brukinsa Evropska unija - slovenščina - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Raptiva Evropska unija - slovenščina - EMA (European Medicines Agency)

raptiva

serono europe limited - efalizumab - psoriaza - imunosupresivi - zdravljenje odraslih bolnikov z zmerno do hudo kronično psoriaze, ki se niso odzvali na ali ki so kontraindikacija za, ali so prenašali na druge sistemske terapije, vključno z ciklosporin se, metotreksatom in puva (glej oddelek 5. 1 - klinična učinkovitost).